David E. Arterburn, MD, MPH

David Arterburn

“It's critical that we find cost-effective ways to treat obesity while reducing weight bias and stigma. My research examines the long-term effects of behavioral, pharmaceutical, and surgical treatments and promotes shared decision-making between patients and their providers.” 

David Arterburn, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine

Biography

David Arterburn, MD, MPH, is a general internist and health services researcher who focuses on finding safe, effective, and non-stigmatizing ways to treat obesity. As an international leader in obesity research, his goal is to help individuals and families make treatment decisions that align with their values while sustaining their health over the long haul.

Dr. Arterburn's research portfolio includes studies of the impact of neighborhood environments on obesity, mindfulness-based interventions for weight loss, obesity pharmacotherapy, the long-term outcomes of bariatric surgery, and implementation of shared decision making tools and processes. He recently led the PCORnet Bariatric Study, a two-year, $4.5 million study comparing the health benefits and safety associated with the main types of bariatric surgery in 41 health systems in the United States. Funded by the Patient-Centered Outcomes Research Institute (PCORI), the study’s results give patients and their health care providers the information they need to decide which type of surgery is best for them. In July 2019, PCORI awarded Dr. Arterburn an additional $2.1 million to incorporate these new results into shared decision making at Kaiser Permanente Washington and the University of Pittsburgh Medical Center.

Over the past decade, Dr. Arterburn has collaborated with Kaiser Permanente Washington's specialty leadership to implement and evaluate shared decision making with patient decision aids to support elective surgical care. The approach has shown great promise for improving the quality of health care while simultaneously lowering the costs of care in some populations.

Dr. Arterburn collaborates extensively in his research and has federally-funded projects related to obesity and bariatric surgery with investigators at University of Washington (UW), Duke University, Harvard, University of Pittsburgh, University of Michigan, Wake Forest, and the Cleveland Clinic.

Dr. Arterburn joined Kaiser Permanente Washington Health Research Institute in 2006. In recognition of his contributions to science, he has been named an honorary Fellow of the American Society of Metabolic and Bariatric Surgery (FASMBS) and a Fellow of the American College of Physicians (FACP) and The Obesity Society (FTOS). Dr. Arterburn is past chair of the Adult Obesity Measurement Advisory Panel sponsored by the National Committee on Quality Assurance, founding chair of the Obesity Society's Health Services Research Section, and past chair of the Health Care Systems Research Network's Obesity Special Interest Group. In 2013 he co-chaired the National Institutes of Health Symposium on the Long-Term Outcomes of Bariatric Surgery. He is also an affiliate professor in the UW Department of Medicine.

RESEARCH INTERESTS AND EXPERIENCE

Recent publications

Kratz M, Hagman DK, Kuzma JN, Foster-Schubert KE, Chan CP, Stewart S, van Yserloo B, Westbrook EO, Arterburn DE, Flum DR, Cummings DE. Improvements in glycemic control after gastric bypass occur despite persistent adipose tissue inflammation. Obesity (Silver Spring). 2016 Jul;24(7):1438-45. doi: 10.1002/oby.21524. Epub 2016 May 26. PubMed

Arterburn D, McCulloch D. Bariatric Surgery for Type 2 Diabetes: Getting Closer to the Long-term Goal.  JAMA. 2016;315(12):1276-7. doi: 10.1001/jama.2016.1884.  PubMed

Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, Bock SN, Landers JT, Kratz M, Foster-Schubert KE, Flum DR. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial.  Diabetologia. 2016 May;59(5):945-53. doi: 10.1007/s00125-016-3903-x. Epub 2016 Mar 17. PubMed

Deen JF, Krieger EV, Slee AE, Arslan A, Arterburn D, Stout KK, Portman MA. Metabolic syndrome in adults with congenital heart disease. J Am Heart Assoc. 2016 Feb 12;5(2). pii: e001132. doi: 10.1161/JAHA.114.001132.  PubMed

Paolino AR, McGlynn EA, Lieu T, Nelson AF, Prausnitz S, Horberg MA, Arterburn DE, Gould MK, Laws RL, Steiner JF. Building a Governance Strategy for CER: The Patient Outcomes Research to Advance Learning (PORTAL) Network Experience.  EGEMS (Wash DC). 2016 Mar 28;4(2):1216. doi: 10.13063/2327-9214.1216. eCollection 2016.  PubMed

 

News

David_Arterburn_overweight_1col.jpg

Filling evidence gaps on obesity treatment

Several new grants will fund research on effectiveness, safety, and equitable use of anti-obesity medications.

Research

Moving_to_Health_1col.jpg

Neighborhood density connected to changes in body mass index for children

Study uses geographic data to track change over time.

Research

VTE_after_bariatric_surgery_1col.jpg

Study finds bariatric surgery linked to substantially lower risk of blood clots long-term

Largest study to date helps patients weigh risks and benefits of surgery.

News

Beverage-tax_1col.jpg

Seattle's Sweetened Beverage Tax linked to improved public health outcomes

An evaluation with KPWHRI researchers looked at the impacts of the tax so far.